1. Impact of heteroresistance on treatment outcomes of people with drug-resistant TB
- Author
-
Crowder, R, Kato-Maeda, M, Schwem, B, dela Tonga, A, Geocaniga-Gaviola, DM, Lopez, E, Valdez, CL, Lim, AR, Hunat, N, Sedusta, AG, Sacopon, CA, Atienza, GAM, Bulag, E, Lim, D, Bascuña, J, Shah, K, Basillio, RP, Berger, CA, Lopez, MCDP, Sen, S, Allender, C, Folkerts, M, Karaoz, U, Brodie, E, Mitarai, S, Garfin, AMC, Ama, MC, Engelthaler, DM, Cattamanchi, A, and Destura, R
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Antimicrobial Resistance ,Orphan Drug ,Tuberculosis ,Rare Diseases ,Emerging Infectious Diseases ,Infectious Diseases ,Biodefense ,2.1 Biological and endogenous factors ,6.1 Pharmaceuticals ,Infection ,Good Health and Well Being ,DR-TB ,Drug resistance-associated mutations ,tuberculosis - Abstract
BackgroundPoor treatment outcomes among people with drug-resistant TB (DR-TB) are a major concern. Heteroresistance (presence of susceptible and resistant Mycobacterium tuberculosis in the same sample) has been identified in some people with TB, but its impact on treatment outcomes is unknown.MethodsWe used targeted deep sequencing to identify mutations associated with DR-TB and heteroresistance in culture samples of 624 people with DR-TB. We evaluated the association between heteroresistance and time to unfavorable treatment outcome using Cox proportional hazards regression.ResultsThe proportion of drug-resistant isolates with a known mutation conferring resistance was lower for streptomycin (45.2%) and second-line injectables (79.1%) than for fluoroquinolones (86.7%), isoniazid (93.2%) and rifampin (96.5%). Fifty-two (8.3%) had heteroresistance, and it was more common for fluoroquinolones (4.6%) than rifampin (2.2%), second-line injectables (1.4%), streptomycin (1.7%), or isoniazid (1.3%). There was no association between heteroresistance and time to unfavorable outcome among people with multidrug-resistant TB (adjusted hazard ratio [aHR] 1.74, 95% CI 0.39-7.72) or pre-extensively DR-TB (aHR 0.65, 95% CI 0.24-1.72).ConclusionsHeteroresistance was relatively common (8.3%) among people with DR-TB in the Philippines. However, we found insufficient evidence to demonstrate an impact on unfavorable treatment outcomes.
- Published
- 2024